Evolent Health, Inc. (EVH) Key Metrics
EVH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $516.7M
- Enterprise value
- $1.26B
- P/E (TTM)
- —
- Forward P/E
- 8.6
- PEG ratio
- 1.93
- Price / sales
- 0.2 10-yr median 1.8
- Price / book
- 1.1 10-yr median 1.3
- EV / EBITDA
- 185.4 10-yr median 43.0
- Dividend yield
- —
- Beta
- 1.02
EVH key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsEVH valuation Price multiples at each fiscal year-end price.
EVH returns How much profit the business earns on the capital it uses.
EVH per-share figures Results divided by the shares outstanding at year-end.
EVH financial health Debt, liquidity and how easily interest is covered.
EVH efficiency & capital use Working capital cycle and where the cash goes.
EVH valuation history
EVH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
EVH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
EVH cash returned to shareholders
EVH price vs earnings per share
EVH key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $456.8M | $1.29B | $3.67B | $2.63B | $2.38B | $1.36B | $745.4M | $1.54B | $791.5M | $666.5M |
| Enterprise value | $1.29B | $1.84B | $4.13B | $2.92B | $2.40B | $1.39B | $1.01B | $1.66B | $674.5M | $607.8M |
| Price / sales | 0.2 | 0.5 | 1.9 | 1.9 | 2.6 | 1.5 | 1.1 | 2.5 | 1.8 | 2.6 |
| Price / book | 1.1 | 1.3 | 3.4 | 3.1 | 3.4 | 2.2 | 0.8 | 1.3 | 0.8 | 0.7 |
| Price / free cash flow | 96.1 | — | 32.3 | — | 173.0 | — | — | — | — | — |
| Price / operating cash flow | 11.8 | 68.8 | 25.8 | — | 61.5 | — | — | — | — | — |
| EV / sales | 0.7 | 0.7 | 2.1 | 2.2 | 2.6 | 1.5 | 1.5 | 2.6 | 1.6 | 2.4 |
| EV / EBITDA | — | 23.0 | — | 66.7 | 43.0 | — | — | — | — | — |
| EV / free cash flow | 272.3 | — | 36.3 | — | 174.1 | — | — | — | — | — |
| Earnings yield | −117.0% | −4.8% | −3.1% | −0.7% | −1.6% | −24.6% | −40.5% | −3.4% | −7.7% | −24.0% |
| Free cash flow yield | 1.0% | −0.5% | 3.1% | −1.9% | 0.6% | −3.4% | −10.5% | −3.9% | −7.1% | −7.7% |
| Dividend yield | 2.4% | 1.6% | 0.5% | 0.6% | 0.1% | 1.5% | 8.2% | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 11.2% | 2.8% | 0.9% | 1.0% | 0.1% | 2.7% | 8.6% | 0.1% | 0.2% | 0.1% |
| Share price at fiscal year-end | $4.00 | $11.25 | $33.03 | $28.08 | $27.67 | $16.03 | $9.05 | $19.95 | $12.30 | $14.80 |
| Per share | ||||||||||
| Revenue per share | $16.43 | $22.28 | $17.65 | $14.43 | $10.55 | $10.89 | $8.34 | $8.11 | $6.76 | $5.64 |
| Earnings per share | −$4.68 | −$0.54 | −$1.02 | −$0.20 | −$0.44 | −$3.94 | −$3.67 | −$0.68 | −$0.94 | −$3.55 |
| Operating cash flow per share | $0.34 | $0.16 | $1.28 | −$0.12 | $0.45 | −$0.19 | −$0.52 | −$0.27 | −$0.43 | −$0.79 |
| Free cash flow per share | $0.04 | −$0.05 | $1.02 | −$0.53 | $0.16 | −$0.54 | −$0.95 | −$0.78 | −$0.87 | −$1.13 |
| Cash per share | $1.33 | $1.43 | $1.73 | $2.01 | $3.09 | $3.93 | $1.25 | $2.95 | $3.71 | $3.97 |
| Book value per share | $3.64 | $8.73 | $9.60 | $9.17 | $8.06 | $7.30 | $11.20 | $15.38 | $16.26 | $20.26 |
| Tangible book value per share | −$7.57 | −$7.12 | −$7.20 | −$3.27 | −$0.14 | $0.07 | $0.51 | $1.11 | $2.75 | $0.59 |
| Dividends per share | $0.10 | $0.18 | $0.17 | $0.16 | $0.02 | $0.24 | $0.74 | — | $0.00 | $0.00 |
| Capex per share | $0.30 | $0.22 | $0.26 | $0.41 | $0.29 | $0.35 | $0.43 | $0.51 | $0.43 | $0.34 |
| Debt per share | $8.67 | $6.22 | $5.80 | $5.08 | $3.26 | $4.24 | $4.48 | $4.44 | $1.89 | $2.67 |
| Shares outstanding | 114.2M | 114.7M | 111.3M | 93.7M | 86.1M | 84.9M | 82.4M | 77.3M | 64.4M | 45.0M |
| Change in shares outstanding | −0.4% | +3.1% | +18.7% | +8.9% | +1.3% | +3.1% | +6.5% | +20.2% | +42.9% | −2.4% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −75.5% | −6.0% | −11.7% | −2.5% | −5.7% | −43.4% | −28.6% | −4.7% | −6.2% | −20.5% |
| Return on invested capital (ROIC) | −0.2% | −2.1% | −4.2% | 0.3% | −4.9% | −22.6% | −19.6% | −3.4% | −6.5% | −27.8% |
| Return on assets (ROA) | −24.1% | −2.4% | −5.0% | −1.2% | −2.6% | −22.5% | −18.8% | −3.5% | −4.8% | −14.4% |
| Return on tangible assets | −86.2% | −8.5% | −13.9% | −2.9% | −5.3% | −38.8% | −48.9% | −8.5% | −13.7% | −50.8% |
| Free cash flow margin | 0.3% | −0.2% | 5.8% | −3.7% | 1.5% | −4.9% | −11.4% | −9.6% | −12.8% | −20.1% |
| Financial health | ||||||||||
| Total debt | $989.7M | $713.7M | $644.8M | $476.1M | $280.5M | $359.8M | $368.8M | $343.6M | $121.4M | $120.3M |
| Cash & short-term investments | $151.9M | $163.5M | $192.8M | $188.2M | $266.3M | $333.4M | $102.8M | $228.3M | $238.4M | $178.9M |
| Net debt | $837.8M | $550.2M | $452.0M | $287.9M | $14.2M | $26.4M | $266.0M | $115.3M | −$117.0M | −$58.6M |
| Debt / equity | 2.38 | 0.71 | 0.60 | 0.55 | 0.40 | 0.58 | 0.40 | 0.29 | 0.12 | 0.13 |
| Debt / assets | 0.52 | 0.28 | 0.24 | 0.26 | 0.20 | 0.24 | 0.25 | 0.20 | 0.09 | 0.10 |
| Net debt / EBITDA | — | 6.87 | — | 6.58 | 0.25 | — | — | — | — | — |
| Current ratio | 1.31 | 0.85 | 1.01 | 1.10 | 1.18 | 1.36 | 1.19 | 3.32 | 2.85 | 2.01 |
| Quick ratio | 1.31 | 0.85 | 1.01 | 2.06 | 1.87 | 2.46 | 1.97 | 2.79 | 2.87 | 2.32 |
| Interest coverage | -0.1 | -1.6 | -1.3 | 0.2 | -1.7 | -9.3 | -21.2 | -8.7 | -20.0 | -328.4 |
| Working capital | $121.1M | −$108.4M | $9.4M | $44.6M | $78.5M | $144.4M | $36.0M | $341.2M | $245.5M | $133.0M |
| Invested capital | $1.25B | $1.55B | $1.52B | $1.15B | $707.8M | $646.0M | $1.19B | $1.30B | $929.3M | $853.5M |
| Tangible asset value | −$864.2M | −$816.2M | −$800.9M | −$306.1M | −$12.4M | $5.6M | $48.5M | $86.2M | $176.9M | $26.6M |
| Net current asset value | −$977.7M | −$936.0M | −$928.9M | −$479.8M | −$201.9M | −$307.2M | −$340.2M | −$45.0M | $111.8M | −$22.8M |
| Graham net-net per share | −$9.54 | −$9.32 | −$9.75 | −$8.40 | −$5.99 | −$7.66 | −$5.87 | −$2.63 | $0.34 | −$2.19 |
| Capital allocation | ||||||||||
| Dividends paid | $11.1M | $20.1M | $18.8M | $14.9M | $1.3M | $20.0M | $61.1M | — | $0 | $0 |
| Share buybacks (net) | $40.0M | $16.6M | $15.3M | $10.4M | $0 | $17.4M | $2.6M | $1.2M | $1.3M | $365,000 |
| Dividends + buybacks / free cash flow | — | — | 29.9% | — | 9.4% | — | — | — | — | — |
| Capex / revenue | 1.8% | 1.0% | 1.5% | 2.8% | 2.8% | 3.2% | 5.2% | 6.3% | 6.4% | 6.1% |
| Capex / operating cash flow | 87.8% | 132.7% | 20.2% | — | 64.5% | — | — | — | — | — |
| Capex / depreciation | 0.29 | 0.21 | 0.23 | 0.57 | 0.42 | 0.48 | 0.58 | 0.89 | 0.86 | 0.90 |
| Stock-based compensation / revenue | 2.1% | 1.6% | 2.1% | 2.5% | 1.8% | 1.6% | 2.3% | 2.8% | 4.7% | 8.9% |
| R&D / revenue | — | — | 1.4% | 2.0% | 2.9% | 2.6% | 2.9% | 2.9% | 4.0% | 4.4% |
| SG&A / revenue | 16.2% | 10.3% | 18.2% | 18.2% | 24.2% | 44.4% | 57.2% | 48.8% | 47.3% | 63.2% |
| Efficiency | ||||||||||
| Days sales outstanding | 71.8 | 61.5 | 65.2 | 52.0 | 51.3 | 39.8 | 42.4 | 44.0 | 46.0 | 43.8 |
| Days of inventory on hand | — | — | -50.5 | -127.6 | -209.1 | -155.9 | -25.5 | 41.9 | -29.7 | -71.8 |
| Days payables outstanding | 17.9 | 12.0 | 12.8 | 27.0 | 35.5 | 18.2 | 65.5 | 105.6 | 58.8 | 71.3 |
| Cash conversion cycle (days) | 53.9 | 49.5 | 1.9 | -102.6 | -193.4 | -134.3 | -48.6 | -19.7 | -42.6 | -99.2 |
| Receivables turnover | 5.08 | 5.93 | 5.60 | 7.02 | 7.12 | 9.16 | 8.60 | 8.29 | 7.94 | 8.33 |
| Payables turnover | 20.44 | 30.32 | 28.52 | 13.51 | 10.27 | 20.06 | 5.57 | 3.46 | 6.20 | 5.12 |
| Inventory turnover | — | — | — | — | — | — | — | 8.71 | — | — |
| Asset turnover | 0.84 | 0.98 | 0.87 | 0.84 | 0.63 | 0.62 | 0.43 | 0.41 | 0.35 | 0.23 |
| Average receivables | $369.0M | $430.7M | $350.7M | $192.6M | $127.5M | $100.9M | $79.9M | $75.6M | $54.8M | $30.5M |
| Average payables | $77.9M | $72.1M | $52.7M | $76.6M | $64.0M | $34.7M | $92.1M | $94.8M | $43.4M | $30.3M |
| Average inventory | — | — | −$208.0M | −$362.1M | −$376.7M | −$297.6M | −$35.8M | $37.6M | −$21.9M | −$30.5M |
| Intangibles / total assets | 67.4% | 71.4% | 69.7% | 64.1% | 49.7% | 41.6% | 58.8% | 64.1% | 66.2% | 73.8% |
Computed from EVH's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
EVH valuation and financial ratios
Evolent Health earned a return on equity of −75.5% and a return on invested capital of −0.2% in fiscal 2025. It ended the year with $989.7 million of debt and $151.9 million in cash and short-term investments, net debt of $837.8 million. It returned $51.1 million to shareholders: $11.1 million in dividends and $40.0 million in share buybacks. The share count rose 153.6% from 45.0M to 114.2M over 9 years.
See the EVH income statement, the EVH chart for price history, or the EVH stock overview for the latest quote and news.
EVH key metrics FAQ
What is Evolent Health's return on equity?
Evolent Health's return on equity (ROE) was −75.5% in fiscal 2025: net income of -$534.5 million on average shareholders' equity of $708.2 million.
What is Evolent Health's ROIC?
Evolent Health's return on invested capital was −0.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Evolent Health have?
Evolent Health had total debt of $989.7 million at the end of fiscal 2025, a debt-to-equity ratio of 2.38.
What is Evolent Health's dividend yield?
Evolent Health paid $11.1 million in dividends in fiscal 2025 ($0.10 per share), a payout ratio of —.
Does Evolent Health buy back its shares?
Yes. Evolent Health spent $40.0 million on net share repurchases in fiscal 2025 Shares outstanding changed −0.4% over the year, to 114.2M..
What is Evolent Health's free cash flow yield?
Evolent Health generated $4.8 million of free cash flow in fiscal 2025, a free cash flow yield of 1.0% on its market value at year-end ($456.8 million).
What is Evolent Health's current ratio?
Evolent Health's current ratio was 1.31 at the end of fiscal 2025: current assets were 1.31 times current liabilities.